1. Academic Validation
  2. Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine)

Synthesis and Antiviral Evaluation of Carbocyclic Nucleoside Analogs of Nucleoside Reverse Transcriptase Translocation Inhibitor MK-8591 (4'-Ethynyl-2-fluoro-2'-deoxyadenosine)

  • J Med Chem. 2018 Oct 25;61(20):9218-9228. doi: 10.1021/acs.jmedchem.8b00141.
François-René Alexandre 1 Rachid Rahali 1 Houcine Rahali 1 Sandra Guillon 2 Thierry Convard 1 Kerry Fillgrove 3 Ming-Tain Lai 3 Jean-Christophe Meillon 2 Min Xu 3 James Small 3 Cyril B Dousson 1 Izzat T Raheem 3
Affiliations

Affiliations

  • 1 Idenix an MSD Company , Cap Gamma, 1682 Rue de la Valsière , 34189 Montpellier Cedex 4, France.
  • 2 Oxeltis , Cap Delta, 1682 Rue de la Valsière , 34189 Montpellier Cedex 4, France.
  • 3 Merck & Co., Inc. , P.O. Box 4, 770 Sumneytown Pike , West Point , Pennsylvania 19486 , United States.
Abstract

MK-8591 (4'-ethynyl-2-fluoro-2'-deoxyadenosine) is a novel nucleoside analog that displays a differentiated mechanism of action as a nucleoside Reverse Transcriptase translocation inhibitor (NRTTI) compared to approved NRTIs. Herein, we describe our recent efforts to explore the impact of structural changes to the properties of MK-8591 through the synthesis and Antiviral evaluation of carbocyclic derivatives. Synthesized analogs were evaluated for their Antiviral activity, and the corresponding triphosphates were synthesized and evaluated in a biochemical assay. 4'-Ethynyl-G derivative (±)-29 displayed a promising IC50 of 33 nM in a hPBMC cell-based Antiviral assay, and its triphosphate (TP), (±)-29-TP, displayed an IC50 of 324 nM in a biochemical RT-polymerase assay. Improved TP anabolite delivery resulting in improved in vitro potency was achieved by preparing the corresponding phosphoramidate prodrug of single enantiomer 29b, with 6-ethoxy G derivative 34b displaying a significantly improved IC50 of 3.0 nM, paving the way for new directions for this novel class of nucleoside analogs.

Figures